OptumRx and CVS Pharmacy Partner to Expand Consumer Choice, Reduce Costs and Improve Health Outcomes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
UBS Raises Price Target on UnitedHealth Group (UNH) Following Investor Day
November 30, 2016 9:49 AM ESTUBS reiterated a Buy rating on UnitedHealth Group (NYSE: UNH), and raised the price target to $193.00 (from $180.00), following the company's investor day. UNH expects its Medicare Advantage enrollment to grow by 700-800K lives in 2017, a 19-22% Y/Y increase. UBS raised 2016 EPS estimates to $9.45 and... More
Leerink Partners Raises Price Target on UnitedHealth Group (UNH) to $195; Reiterates Outperform
November 30, 2016 7:46 AM ESTLeerink Partners reiterated an Outperform rating on UnitedHealth Group (NYSE: UNH), and raised the price target to $195.00 (from $185.00), following a company update. EPS guidance of $9.30 - $9.60 came in better than the Street expectation of $9.16. The EPS upside is driven by better than expected top-line growth in MA, and Optum as well as the ObamaCare tax holiday.
Analyst Ana Gupte, commented, "We remain bullish on UNH (OP) and reiterate our top pick status on the name while raising estimates and PT to $195. In addition to surprising meaningfully to the upside on 2017 guidance,... More
CVS's (CVS) OptumRx Win Belies Risk - Evercore ISI
November 29, 2016 10:01 AM ESTEvercore ISI analyst Ross Muken was positive on CVS Health (NYSE: CVS) after the company OptumRx (UNH) announced that they will offer the ability for OptumRx customers to fill 90-day prescriptions at either CVS retail pharmacies or via OptumRx home delivery. Additionally, the companies will offer improved consumer engagement tools and provide a shared pharmacy... More
